Results 71 to 80 of about 100,641 (375)

Disease Progression in Multiple System Atrophy: The ASPIRE Multi‐Modal Biomarker Study

Annals of Neurology, EarlyView.
Objective The objective of this study was to characterize changes in candidate biomarkers in early multiple system atrophy (MSA) and identify baseline predictors of faster progression. Methods This 1‐year, multicenter, prospective study assessed clinical, neuroimaging (3T‐magnetic resonance imaging [MRI], dopamine transporter single‐photon emission ...
Margherita Fabbri, Natalia del Campo, Wassilios G. Meissner, Vanessa Rousseau, Agnès Sommet, Pierre Payoux, Pierre Gantet, Amel Drif, Hélène Catalá, Claire Thalamas, Christine Tranchant, Franck Durif, Ana Marques, Alexandre Eusebio, Luc Defebvre, Jean‐Christophe Corvol, Stéphane Thobois, Anthime Flaus, Anne‐Gaelle Corbille, Solène Frismand, Beverley Patterson, Alexandra Foubert‐Samier, Anne Pavy‐Le Traon, Germain Arribarat, Patrice Péran, Olivier Rascol, for the ASPIRE Study Group   +26 more
wiley   +1 more source

DOPAMINE DYSREGULATION SYNDROME IN PARKINSON’S DISEASE AND APPROACHES TO ITS CORRECTION WITH DRUGS

Klinicist, 2017
The objective is to describe a clinical case of dopamine dysregulation syndrome (DDS) with compulsive intake of large doses of levodopa in a patient with Parkinson’s disease (PD).Materials and methods. Male patient R., born in 1956, has had PD since 2004
S. M. Omarova, N. V. Fedorova
doaj   +1 more source

A double-blind study of the efficacy of apomorphine and its assessment in "off-periods in Parkinson's disease [PDF]

, 1993
Five patients with idiopathic Parkinson's disease with severe response fluctuations were selected for a randomized double-blind placebo-controlled study, concerning the clinical effects of subcutaneous apomorphine and its assessment in `off¿-periods. The
Essink, A.W.G., Jansen, E.N.H., Laar, T. van, Neef, C., Oosterloo, S.   +4 more
core   +3 more sources

Freezing of Gait can persist after an acute levodopa challenge in Parkinson’s disease

npj Parkinson's Disease, 2019
Study objectives included testing whether presumed levodopa-unresponsive freezing of gait (FOG) in Parkinson’s disease (PD) actually persists in the presence of adequate dopaminergic dosing and to investigate whether the presence of other parkinsonian ...
J. Lucas McKay, F. Goldstein, B. Sommerfeld, Douglas Bernhard, Sahyli Perez Parra, S. Factor   +5 more
semanticscholar   +1 more source

Adherence to the Mediterranean and Mediterranean‐Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) Diets and Parkinson's Disease Incidence in Women: Results from the Prospective E3N Cohort

Annals of Neurology, EarlyView.
Objective The evidence regarding adherence to dietary patterns and Parkinson's disease (PD) risk is inconsistent. Because of the long prodromal PD phase, reverse causation represents a major threat to investigations of diet in relation to PD. We examined whether adherence to the Mediterranean (MED) and Mediterranean‐Dietary Approaches to Stop ...
Mariem Hajji‐Louati, Emmanuelle Correia, Pei‐Chen Lee, Fanny Artaud, Emmanuel Roze, Francesca Romana Mancini, Alexis Elbaz   +6 more
wiley   +1 more source

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

Neuropsychiatric Disease and Treatment, 2008
David J BrooksDivision of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UKAbstract: After 40 years of clinical experience, levodopa remains the gold standard treatment for Parkinson’s disease (PD) despite ...
David J Brooks
doaj  

A phase I study to evaluate the effect of high-dose carbidopa on levodopa pharmacokinetics

Frontiers in Pharmacology
Levodopa is the gold standard treatment for Parkinson’s disease. However, a high unmet medical need exists for longer-lasting oral levodopa formulations to achieve sustained motor improvement with reduced risk of the effect wearing off.
Akane Hayashi, Atsushi Hosomi, Shinsaku Kihara, Masato Nishi, Saori Torisawa, Yoshiumi Ouchi, Hidenori Takada, Junichi Enokizono   +7 more
doaj   +1 more source

Levodopa treatment patterns in Parkinson’s disease: A retrospective chart review

Clinical Parkinsonism & Related Disorders, 2022
Background: Medication regimens for Parkinson’s disease (PD) may change as the disease progresses, symptoms fluctuate, or medication-related adverse events occur.
Prakash Navaratnam, Steve Arcona, Howard S. Friedman, Matthew Leoni, Rahul Sasane   +4 more
doaj   +1 more source

The effectiveness of traditional methods and altered auditory feedback in improving speech rate and intelligibility in speakers with Parkinson's disease [PDF]

, 2010
Communication problems are a frequent symptom for people with Parkinson's disease (PD) which can have a significant impact on their quality-of-life. Deciding on the right management approach can be problematic though, as, with the exception of LSVT (R ...
Dobinson, Corinne, Howell, Peter, Kröger, Bernd, Lowit, Anja, Timmins, Claire   +4 more
core   +1 more source

Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation

Annals of Neurology, EarlyView.
Objective Whether cognitive decline in patients with Parkinson's disease (PD) carrying GBA1 variants is accelerated after subthalamic deep brain stimulation (STN‐DBS) remains controversial. Clarifying long‐term cognitive outcomes is essential for informed decision making.
Moritz A. Loeffler, Philipp Klocke, Isabel Wurster, Stefanie Lerche, Idil Cebi, Thomas Gasser, Alireza Gharabaghi, Kathrin Brockmann, Daniel Weiss   +8 more
wiley   +1 more source